The latest peptide research, lab-quality, and regulatory news — summarized in plain language and linked to primary sources. For informational use only; not medical advice. 21+.
-
Research Note: Review Surveys AI-Driven Antimicrobial Peptide Discovery
A review in Frontiers in Bioinformatics surveys how big data, modeling and AI are advancing computational antimicrobial peptide (AMP) discovery — a methods-focused look at the research.
-
FDA Staff Recommend Against Adding Seven Peptides to the 503A Compounding List
FDA briefing documents recommend against adding BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon to the 503A compounding list before the July 23–24 PCAC meeting.
-
Retatrutide’s Phase 3 diabetes data published in The Lancet and presented at ADA 2026
Retatrutide’s first Phase 3 type 2 diabetes trial, TRANSCEND-T2D-1, was published in The Lancet and presented with TRIUMPH-1 obesity data at ADA 2026.
-
New analytical method improves de novo sequencing of short peptides
Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.
-
Why a batch-matched Certificate of Analysis still anchors research-peptide quality
As scrutiny of research-peptide quality grows, one principle keeps surfacing: a Certificate of Analysis (COA) is only meaningful when it is tied to the exact batch in hand and reports more than a single purity figure. A useful COA generally documents several things together: identity confirmation (commonly by mass spectrometry), purity (typically by HPLC), and…
-
Study compares semaglutide, tirzepatide, and retatrutide in a genetic obesity mouse model
A peer-reviewed study in the International Journal of Obesity compares three GLP-1–class peptides — semaglutide, tirzepatide, and retatrutide — in a genetic mouse model of obesity. The researchers used MC4R-knockout mice, which lack a receptor central to the brain’s appetite-regulating melanocortin pathway and develop obesity, insulin resistance, and markers of liver stress. Over a 21-day…
-
Retatrutide reports ~28% average weight loss in first Phase 3 obesity trial
Eli Lilly has reported topline results from TRIUMPH-1, the first Phase 3 obesity trial of the triple-agonist peptide retatrutide. Retatrutide acts on three receptors — GLP-1, GIP, and glucagon — distinguishing it from single- and dual-agonist compounds in the same class. According to the company’s announcement, mean body-weight reduction rose with dose: roughly 19% at…
-
PCAC peptide hearing July 23–24: key deadlines arrive this month
Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…
-
FDA comment window on excluding compounded GLP-1s closes June 29
The FDA’s public comment window on whether to keep three popular GLP-1 medicines off the 503B bulk drug substances list closes June 29, 2026. In an April 30, 2026 proposal, the FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances, given that FDA-approved versions…
-
FDA sets July 23–24 hearing on seven research peptides
The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.
-
FDA proposes excluding semaglutide and tirzepatide from the 503B bulks list
The FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulk substances list. A public comment period is open, closing on or around June 29, 2026.
-
BPC-157 removed from 503A Category 2; compounding status still pending
BPC-157 came off the 503A Category 2 safety-risk list in April 2026 but is not yet on an approved bulks list, leaving its compounding status unresolved ahead of the July PCAC review.
-
Independent lab testing renews scrutiny of research-peptide purity
Third-party analyses report a substantial share of online research peptides miss stated purity, and note that endotoxin can matter even at ~99% purity — reinforcing why COAs are worth reading.
-
GLP-1 research expands: oral Wegovy and ‘beyond GLP-1’ targets
An oral semaglutide 25 mg became available in January 2026, and ADA 2026 featured next-generation “beyond GLP-1” approaches and new mechanism findings.